OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis $0.27 +0.02 (+7.14%) (As of 09/13/2024 05:38 PM ET) Add Compare Share Share Today's Range$0.26▼$0.2850-Day Range$0.21▼$0.3052-Week Range$0.18▼$0.43Volume24,800 shsAverage Volume33,093 shsMarket Capitalization$21.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get DIAGNOS alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About DIAGNOS Stock (OTCMKTS:DGNOF)DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More DGNOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGNOF Stock News HeadlinesAugust 22, 2024 | globenewswire.comDIAGNOS Announces Date of Annual General and Special Meeting of ShareholdersAugust 20, 2024 | globenewswire.comDIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health CanadaSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?June 5, 2024 | globenewswire.comDIAGNOS Announces Closing of Second and Final Tranche of Private PlacementMay 21, 2024 | globenewswire.comDIAGNOS celebrates the launch of Labtician's new screening service for diabetic retinopathy in Ontario and renews its distribution agreementMay 9, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementMay 6, 2024 | globenewswire.comDIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024April 16, 2024 | globenewswire.comDIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certificationSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?April 9, 2024 | globenewswire.comDIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11thApril 3, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsApril 2, 2024 | globenewswire.comDIAGNOS Welcomes Dr. Philippe Couillard to its Board of DirectorsMarch 22, 2024 | globenewswire.comDIAGNOS Announces Closing of Second and Final Tranche of Private PlacementMarch 4, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsFebruary 29, 2024 | globenewswire.comDIAGNOS Welcomes Mr. Michael Braeuel to its Board of DirectorsFebruary 27, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementFebruary 23, 2024 | globenewswire.comDiagnos Announces Variation in One Insider Ownership of Common SharesFebruary 21, 2024 | globenewswire.comDIAGNOS recognized as a Top TSX Venture Exchange CompanySee More Headlines Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/17/2024Today9/14/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CUSIPN/A CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,310,000.00 Net Margins-1,898.33% Pretax Margin-1,833.70% Return on EquityN/A Return on Assets-375.70% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$130,000.00 Price / Sales169.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-9.00Miscellaneous Outstanding Shares81,436,000Free FloatN/AMarket Cap$21.99 million OptionableNot Optionable Beta0.17 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, President & Executive ChairmanMr. Marc-André MassueVP of Finance, CFO & SecretaryMr. Yves-Stéphane CoutureChief Operating OfficerMr. Martin BelandDirector of MarketingKey CompetitorsThomas Cook GroupOTCMKTS:TCKGYAtosOTCMKTS:AEXAYDatalexOTCMKTS:DLEXYWentworth ResourceOTCMKTS:WENTFTotal BrainOTCMKTS:BRRZYView All Competitors DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed this year? DIAGNOS's stock was trading at $0.3050 at the beginning of 2024. Since then, DGNOF stock has decreased by 11.5% and is now trading at $0.27. View the best growth stocks for 2024 here. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) announced its quarterly earnings results on Wednesday, July, 17th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DGNOF) was last updated on 9/14/2024 by MarketBeat.com Staff From Our PartnersThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | Sponsored"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion...Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
